{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:21:09Z","timestamp":1790392869580,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1124\/dmd.113.055996","type":"journal-article","created":{"date-parts":[[2014,1,3]],"date-time":"2014-01-03T03:17:26Z","timestamp":1388719046000},"page":"586-595","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Modeling Human Nonalcoholic Steatohepatitis-Associated Changes in Drug Transporter Expression Using Experimental Rodent Models"],"prefix":"10.1016","volume":"42","author":[{"given":"Mark J.","family":"Canet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhiannon N.","family":"Hardwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April D.","family":"Lake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anika L.","family":"Dzierlenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan J.","family":"Cherrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.113.055996_bib1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/07853890802552437","article-title":"New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD)","volume":"41","author":"Ali","year":"2009","journal-title":"Ann Med"},{"key":"10.1124\/dmd.113.055996_bib2","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1152\/physrev.1979.59.3.719","article-title":"Hypothalamic and genetic obesity in experimental animals: an autonomic and endocrine hypothesis","volume":"59","author":"Bray","year":"1979","journal-title":"Physiol Rev"},{"key":"10.1124\/dmd.113.055996_bib3","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1124\/dmd.112.046177","article-title":"Altered arsenic disposition in experimental nonalcoholic fatty liver disease","volume":"40","author":"Canet","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.055996_bib4","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1096\/fj.04-2291fje","article-title":"A high-fat diet leads to the progression of non-alcoholic fatty liver disease in obese rats","volume":"19","author":"Carmiel-Haggai","year":"2005","journal-title":"FASEB J"},{"key":"10.1124\/dmd.113.055996_bib5","doi-asserted-by":"crossref","first-page":"G48","DOI":"10.1152\/ajpgi.00317.2012","article-title":"The hepatic bile acid transporters Ntcp and Mrp2 are downregulated in experimental necrotizing enterocolitis","volume":"304","author":"Cherrington","year":"2013","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1124\/dmd.113.055996_bib6","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.freeradbiomed.2009.11.007","article-title":"Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis","volume":"48","author":"Chowdhry","year":"2010","journal-title":"Free Radic Biol Med"},{"key":"10.1124\/dmd.113.055996_bib7","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1517\/17425255.2012.656087","article-title":"Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions","volume":"8","author":"Clarke","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.113.055996_bib8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/B978-0-12-398339-8.00004-5","article-title":"Genetic polymorphisms affecting drug metabolism: recent advances and clinical aspects","volume":"63","author":"Daly","year":"2012","journal-title":"Adv Pharmacol"},{"key":"10.1124\/dmd.113.055996_bib9","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1055\/s-0030-1267539","article-title":"Novel insights into the pathophysiology of nonalcoholic fatty liver disease","volume":"30","author":"Feldstein","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1124\/dmd.113.055996_bib10","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00204-008-0312-z","article-title":"Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis","volume":"82","author":"Fisher","year":"2008","journal-title":"Arch Toxicol"},{"key":"10.1124\/dmd.113.055996_bib11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejphar.2009.04.002","article-title":"Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats","volume":"613","author":"Fisher","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/dmd.113.055996_bib12","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1124\/dmd.109.027466","article-title":"Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease","volume":"37","author":"Fisher","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.055996_bib13","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1124\/dmd.110.035006","article-title":"Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease","volume":"38","author":"Hardwick","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.055996_bib14","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1124\/dmd.111.041012","article-title":"Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease","volume":"39","author":"Hardwick","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.055996_bib15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1124\/dmd.111.041095","article-title":"Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis","volume":"40","author":"Hardwick","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.055996_bib16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrgastro.2010.191","article-title":"Animal models of nonalcoholic fatty liver disease","volume":"8","author":"Hebbard","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1124\/dmd.113.055996_bib17","doi-asserted-by":"crossref","first-page":"504","DOI":"10.2133\/dmpk.DMPK-13-RG-021","article-title":"Altered pharmacokinetics of cimetidine caused by down-regulation of renal rat organic cation transporter 2 (rOCT2) after liver ischemia-reperfusion injury","volume":"28","author":"Ikemura","year":"2013","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.113.055996_bib18","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1098\/rstb.2005.1685","article-title":"Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy","volume":"360","author":"Ingelman-Sundberg","year":"2005","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1124\/dmd.113.055996_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-398339-8.00001-X","article-title":"Membrane transporters in drug development","volume":"63","author":"Keogh","year":"2012","journal-title":"Adv Pharmacol"},{"key":"10.1124\/dmd.113.055996_bib20","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1046\/j.1440-1746.2003.03198.x","article-title":"Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies","volume":"18","author":"Kirsch","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1124\/dmd.113.055996_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.109.002014","article-title":"Xenobiotic, bile acid, and cholesterol transporters: function and regulation","volume":"62","author":"Klaassen","year":"2010","journal-title":"Pharmacol Rev"},{"key":"10.1124\/dmd.113.055996_bib22","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1124\/dmd.113.055996_bib23","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1124\/dmd.111.040592","article-title":"Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease","volume":"39","author":"Lake","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.055996_bib24","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.taap.2013.01.022","article-title":"Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease","volume":"268","author":"Lake","year":"2013","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1124\/dmd.113.055996_bib25","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1111\/j.1440-1746.2008.05543.x","article-title":"Animal models of NASH: getting both pathology and metabolic context right","volume":"23","author":"Larter","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1124\/dmd.113.055996_bib26","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","article-title":"Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies","volume":"279","author":"Lazarou","year":"1998","journal-title":"JAMA"},{"key":"10.1124\/dmd.113.055996_bib27","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1172\/JCI8814","article-title":"CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis","volume":"105","author":"Leclercq","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1124\/dmd.113.055996_bib28","doi-asserted-by":"crossref","first-page":"9402","DOI":"10.1021\/ac801263r","article-title":"Electrochemical branched-DNA assay for polymerase chain reaction-free detection and quantification of oncogenes in messenger RNA","volume":"80","author":"Lee","year":"2008","journal-title":"Anal Chem"},{"key":"10.1124\/dmd.113.055996_bib29","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1124\/dmd.107.015107","article-title":"Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease","volume":"35","author":"Lickteig","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.055996_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40265-012-0004-0","article-title":"Nonalcoholic fatty liver disease: current issues and novel treatment approaches","volume":"73","author":"Lomonaco","year":"2013","journal-title":"Drugs"},{"key":"10.1124\/dmd.113.055996_bib31","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.urology.2009.01.087","article-title":"Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA","volume":"74","author":"Lu","year":"2009","journal-title":"Urology"},{"key":"10.1124\/dmd.113.055996_bib32","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/nyas.12016","article-title":"Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals","volume":"1281","author":"Masuoka","year":"2013","journal-title":"Ann N Y Acad Sci"},{"key":"10.1124\/dmd.113.055996_bib33","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/hep.21874","article-title":"Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet","volume":"46","author":"Matsuzawa","year":"2007","journal-title":"Hepatology"},{"key":"10.1124\/dmd.113.055996_bib34","first-page":"S17","article-title":"Pathophysiology of nonalcoholic steatohepatitis","volume":"40","author":"McCullough","year":"2006","journal-title":"J Clin Gastroenterol"},{"key":"10.1124\/dmd.113.055996_bib35","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jhep.2003.09.020","article-title":"The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance","volume":"40","author":"Rinella","year":"2004","journal-title":"J Hepatol"},{"key":"10.1124\/dmd.113.055996_bib36","doi-asserted-by":"crossref","first-page":"G1035","DOI":"10.1152\/ajpgi.00199.2004","article-title":"Obese and diabetic db\/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin","volume":"287","author":"Sahai","year":"2004","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1124\/dmd.113.055996_bib37","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000282097","article-title":"Animal models of non-alcoholic steatohepatitis: of mice and man","volume":"28","author":"Schattenberg","year":"2010","journal-title":"Dig Dis"},{"key":"10.1124\/dmd.113.055996_bib38","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1345\/aph.1P592","article-title":"Adverse drug reaction deaths reported in United States vital statistics, 1999-2006","volume":"46","author":"Shepherd","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1124\/dmd.113.055996_bib39","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jhep.2004.03.015","article-title":"Oral glucose tolerance deteriorates in rats fed with methionine choline deficient diet","volume":"41","author":"Tahan","year":"2004","journal-title":"J Hepatol"},{"key":"10.1124\/dmd.113.055996_bib40","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.3748\/wjg.v18.i19.2300","article-title":"Animal models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"18","author":"Takahashi","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1124\/dmd.113.055996_bib41","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1097\/NND.0b013e31819b5f0b","article-title":"Creative strategies to improve patient safety: allergies and adverse drug reactions","volume":"27","author":"Valente","year":"2011","journal-title":"J Nurses Staff Dev"},{"key":"10.1124\/dmd.113.055996_bib42","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1097\/SMJ.0b013e3181f0c866","article-title":"Adverse drug reactions: Part I","volume":"103","author":"Wooten","year":"2010","journal-title":"South Med J"},{"key":"10.1124\/dmd.113.055996_bib43","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/hep.21655","article-title":"Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis","volume":"45","author":"Yamaguchi","year":"2007","journal-title":"Hepatology"},{"key":"10.1124\/dmd.113.055996_bib44","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/tpj.2012.42","article-title":"Pharmacogenomics of phase II metabolizing enzymes and drug transporters: clinical implications","volume":"13","author":"Yiannakopoulou","year":"2013","journal-title":"Pharmacogenomics J"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624113815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624113815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.113.055996","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:33:35Z","timestamp":1739907215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624113815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0090955624113815"],"URL":"https:\/\/doi.org\/10.1124\/dmd.113.055996","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modeling Human Nonalcoholic Steatohepatitis-Associated Changes in Drug Transporter Expression Using Experimental Rodent Models","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.113.055996","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2014 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}